| scholarly article | Q13442814 |
| P50 | author | Giuseppe Pantaleo | Q88061163 |
| P2093 | author name string | Qi Wang | |
| Zheng Zhang | |||
| Lishan Su | |||
| Liang Cheng | |||
| Yves Levy | |||
| Guangming Li | |||
| Gerard Zurawski | |||
| Haisheng Yu | |||
| Jianping Ma | |||
| Fumihiko Yasui | |||
| Matthieu Perreau | |||
| Riddhima Banga | |||
| Sandra Zurawski | |||
| P2860 | cites work | CD40 AND CD154 IN CELL-MEDIATED IMMUNITY | Q22255634 |
| HIV therapeutic vaccines: moving towards a functional cure | Q27002180 | ||
| Delivering HIV Gagp24 to DCIR Induces Strong Antibody Responses In Vivo | Q27300713 | ||
| Immunopathogenesis and immunotherapy in AIDS virus infections | Q28183667 | ||
| Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia | Q28254584 | ||
| Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection | Q28304764 | ||
| Dendritic cells: specialized and regulated antigen processing machines | Q29617085 | ||
| Taking dendritic cells into medicine | Q29619243 | ||
| New CD4+ and CD8+ T cell responses induced in chronically HIV type-1-infected patients after immunizations with an HIV type 1 lipopeptide vaccine | Q33249455 | ||
| Multiepitopic B- and T-cell responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine | Q33797285 | ||
| Immunologic strategies for HIV-1 remission and eradication | Q33896523 | ||
| Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. | Q33902330 | ||
| The XC chemokine receptor 1 is a conserved selective marker of mammalian cells homologous to mouse CD8alpha+ dendritic cells | Q33902379 | ||
| Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha+ dendritic cells | Q33902421 | ||
| HIV Infection, Inflammation, Immunosenescence, and Aging | Q34150710 | ||
| Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice | Q34180174 | ||
| Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy | Q34290545 | ||
| Dendritic-cell-based therapeutic cancer vaccines | Q34360094 | ||
| HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication | Q34448446 | ||
| Humanized mice in translational biomedical research | Q34607151 | ||
| Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates. | Q34880294 | ||
| B cell follicle sanctuary permits persistent productive simian immunodeficiency virus infection in elite controllers | Q35058635 | ||
| Eradicating HIV-1 infection: seeking to clear a persistent pathogen | Q35252186 | ||
| Targeting HIV-1 Env gp140 to LOX-1 Elicits Immune Responses in Rhesus Macaques | Q35989484 | ||
| Vaccine Adjuvants: Putting Innate Immunity to Work | Q36168232 | ||
| Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance | Q36376611 | ||
| Clinical safety of HIV lipopeptides used as vaccines in healthy volunteers and HIV-infected adults | Q36444377 | ||
| In Vitro Reactivation of Replication-Competent and Infectious HIV-1 by Histone Deacetylase Inhibitors | Q36523946 | ||
| Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production | Q36547664 | ||
| Functional Specialty of CD40 and Dendritic Cell Surface Lectins for Exogenous Antigen Presentation to CD8(+) and CD4(+) T Cells | Q36754182 | ||
| The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T-cell lymphoma patients | Q36802272 | ||
| Antigen delivery to early endosomes eliminates the superiority of human blood BDCA3+ dendritic cells at cross presentation | Q36822696 | ||
| Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy | Q36950611 | ||
| The Effect of Latency Reversal Agents on Primary CD8+ T Cells: Implications for Shock and Kill Strategies for Human Immunodeficiency Virus Eradication | Q37034469 | ||
| Humanized mice for immune system investigation: progress, promise and challenges | Q37111994 | ||
| Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs | Q37273652 | ||
| Reactivation of latent HIV-1 in central memory CD4⁺ T cells through TLR-1/2 stimulation | Q37305160 | ||
| Targeting concatenated HIV antigens to human CD40 expands a broad repertoire of multifunctional CD4+ and CD8+ T cells | Q37385041 | ||
| Blocking type I interferon signaling enhances T cell recovery and reduces HIV-1 reservoirs | Q37545050 | ||
| HIV-1 immunopathogenesis in humanized mouse models | Q37676228 | ||
| Dendritic cell-targeted vaccines | Q38218671 | ||
| Superiority in Rhesus Macaques of Targeting HIV-1 Env gp140 to CD40 versus LOX-1 in Combination with Replication-Competent NYVAC-KC for Induction of Env-Specific Antibody and T Cell Responses | Q38757011 | ||
| Therapeutic vaccines and immunological intervention in HIV infection: a paradigm change | Q38949441 | ||
| Humanized Mouse Models for Human Immunodeficiency Virus Infection. | Q39459609 | ||
| The TLR9 agonist MGN1703 triggers a potent type I interferon response in the sigmoid colon. | Q40098403 | ||
| Type I interferons suppress viral replication but contribute to T cell depletion and dysfunction during chronic HIV-1 infection | Q40160105 | ||
| Toll-like receptor 3 activation selectively reverses HIV latency in microglial cells | Q40343146 | ||
| Characterization of a multi-lipopeptides mixture used as an HIV-1 vaccine candidate | Q40795438 | ||
| Superior antigen cross-presentation and XCR1 expression define human CD11c+CD141+ cells as homologues of mouse CD8+ dendritic cells | Q40952120 | ||
| Dendritic cell-based therapeutic vaccine elicits polyfunctional HIV-specific T-cell immunity associated with control of viral load | Q42205079 | ||
| Lipopeptides induce cell-mediated anti-HIV immune responses in seronegative volunteers | Q42653193 | ||
| Dendritic cell-targeted vaccines--hope or hype? | Q42696952 | ||
| Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patients. | Q44142940 | ||
| Studies in subjects with long-term nonprogressive human immunodeficiency virus infection | Q44369963 | ||
| Human innate responses and adjuvant activity of TLR ligands in vivo in mice reconstituted with a human immune system | Q49663116 | ||
| Delivery of antigen to CD40 induces protective immune responses against tumors. | Q51976812 | ||
| Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1. | Q53592113 | ||
| HIV: Shock and kill. | Q55056512 | ||
| Selective transduction of dendritic cells in human lymph nodes and superior induction of high-avidity melanoma-reactive cytotoxic T cells by a CD40-targeted adenovirus | Q64374855 | ||
| Infection of the SCID-hu mouse by HIV-1 | Q67985380 | ||
| A potent adjuvant effect of CD40 antibody attached to antigen | Q73303811 | ||
| HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors | Q78342521 | ||
| Reconstitution of a functional human immune system in immunodeficient mice through combined human fetal thymus/liver and CD34+ cell transplantation | Q82252349 | ||
| Sustained control of viremia following therapeutic immunization in chronically HIV-1-infected individuals | Q82389408 | ||
| Internalization and endosomal degradation of receptor-bound antigens regulate the efficiency of cross presentation by human dendritic cells | Q84569562 | ||
| P433 | issue | 10 | |
| P304 | page(s) | 4387-4396 | |
| P577 | publication date | 2018-08-27 | |
| P1433 | published in | Journal of Clinical Investigation | Q3186904 |
| P1476 | title | TLR3 agonist and CD40-targeting vaccination induces immune responses and reduces HIV-1 reservoirs. | |
| P478 | volume | 128 |
| Q92667638 | A pathogenic role of plasmacytoid dendritic cells in autoimmunity and chronic viral infection |
| Q93196555 | Anti-HIV potency of T-cell responses elicited by dendritic cell therapeutic vaccination |
| Q60909641 | Application of built-in adjuvants for epitope-based vaccines |
| Q89694033 | HIV infection suppresses TLR3 activation-mediated antiviral immunity in microglia and macrophages |
| Q60048646 | HIV-1 T cell epitopes targeted to Rhesus macaque CD40 and DCIR: A comparative study of prototype dendritic cell targeting therapeutic vaccine candidates |
| Q61812881 | The Incorporation of Host Proteins into the External HIV-1 Envelope |
Search more.